Striking dichotomy in outcome of MYCN-amplified neuroblastoma in the contemporary era Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Gene Amplification
  • Neuroblastoma
  • Nuclear Proteins
  • Oncogene Proteins

abstract

  • Patients with MYCN(-), high-risk neuroblastoma display a broad, continuous spectrum with regard to response and outcome, whereas MYCN(+) patients either have an excellent response to induction associated with good long-term outcome or develop early progressive disease with a poor outcome. This extreme dichotomy in the clinical course of MYCN(+) patients points to underlying biologic differences with MYCN(+) neuroblastoma, the elucidation of which may have far-reaching implications, including improved risk classification at diagnosis and the identification of targets for treatment.

publication date

  • July 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4326052

Digital Object Identifier (DOI)

  • 10.1002/cncr.28687

PubMed ID

  • 24691684

Additional Document Info

start page

  • 2050

end page

  • 9

volume

  • 120

number

  • 13